Novacell Technology Co., Ltd. (Novacell), a Korean biotechnology company that develops peptide immunotherapy, as an affiliate of Donggu Biopharmaceutical, a pharmaceutical/bio-specialized company, and 48 Hour Discovery Inc., (48HD), a Canadian biopharmaceutical company specializing in the development of new peptide drugs, announced on December 15th that they have signed a joint research and technology transfer option contract with the company.
Through this contract, Novacell will develop a next-generation version of the cyclic peptide ligand targeting the G protein-binding receptor (GPCR) FPR2, which is involved in resolving inflammation. It will also obtain a license option to develop new pipelines for other GPCRs using the 48HD molecular discovery platform.
48HD’s genetically-encoded cyclic peptide library technology complements Novacell’s chemically produced linear peptide library platform (PS-SPCL). By incorporating 48HD platform technology, Novacell will discover and optimize more specific and stable FPR2-target ligands that can be developed as orally delivered therapeutics.
48HD, which has a number of drug discovery projects underway with global pharmaceutical companies, will use its 48HD molecular discovery platform to develop a custom billion-scale genetically encoded libraries to fuel the next-generation pipelines of NovaCell Technology.
Novacell used its own functional peptide discovery platform technology to develop NCP112: a miniaturized FPR2-specific peptide ligand. Using the pleiotropic anti-inflammatory properties of NCP112, the company is developing immunotherapy drugs for various diseases such as atopic dermatitis, dry eye, asthma, and rheumatoid arthritis.
For NCP112, Novacell received assistance for the pre-clincal program from the Ministry of New Drug Development Project and entered the clinical development stage by applying for IND for a phase 1/2 clinical trial in Korea.
Also, based on its excellent efficacy against dry eye syndrome, a technology transfer contract was signed with Huons Group (http://en.huons.com/) to develop a new eye disease treatment. In addition, given the efficacy of suppressing excessive inflammatory reactions, the development of immunotherapy drugs for viral infections such as Covid 19 is underway.
NovaCell recently completed attracting a total of 13 billion won in pre-IPO investment from 10 venture capital and KOSDAQ-listed companies in recognition of the future value of the pipeline. Plans to list the NovaCell Technology on KOSDAQ in 2021 are expected to gain momentum with the completion of non-clinical development and technology transfer.
Also, based on its excellent efficacy against dry eye syndrome, a technology transfer contract was signed with Huons Group (http://en.huons.com/) to develop a new eye disease treatment. In addition, given the efficacy of suppressing excessive inflammatory reactions, the development of immunotherapy drugs for viral infections such as Covid 19 is underway.
NovaCell recently completed attracting a total of 13 billion won in pre-IPO investment from 10 venture capital and KOSDAQ-listed companies in recognition of the future value of the pipeline. Plans to list the NovaCell Technology on KOSDAQ in 2021 are expected to gain momentum with the completion of non-clinical development and technology transfer.
(From the PharmNews website of the Korean Business Journal. 출처 : 팜뉴스http://www.pharmnews.com)
View the original post at pharmnews.com
